Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study

Autor: Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B. Seibel, Michael B. Murphy, Linda Crew, Joel Goldstein, Andrea Crocker, Laura A. Vitale, Pamela A. Morani, Lawrence J. Thomas, Thomas R. Hawthorne, Tibor Keler, Diane Young, Elizabeth Crowley, Martin Kankam, Margo Heath‐Chiozzi

Publikováno v: Allergy. 77:2393-2403

Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients have limited benefit suggest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b83e55af5beb6cbb26e914b5749638d3
https://doi.org/10.1111/all.15262

Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria

Autor: Marcus Maurer, Martin Metz, John Anderson, Neetu Talreja, Hugh Windom, Diego Alvarado, Elizabeth Crowley, Diane Young, Kunal Merchant, ELsa Paradise, Margo Heath-Chiozzi, Jonathan Bernstein

Publikováno v: Journal of Allergy and Clinical Immunology. 151:AB133

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c984bbcb5efcad34612cd98a14672fc8
https://doi.org/10.1016/j.jaci.2022.12.418

Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C

Autor: Jacob Lalezari, Monica Kumar, Joann Zamparo, Robert Wolf, B. Freilich, Jeffrey E. Saffitz, Philip D. Yin, Eric Hughes, Adrian F. Hernandez, Kyle Brown, Tariq Ahmad, Margo Heath-Chiozzi, Dessislava Dimitrova, Andrew J. Muir, Doug Manion, Mitchell L. Shiffman, Paul J. Pockros

Publikováno v: Hepatology. 62:409-416

Treatment for chronic hepatitis C virus (HCV) infection is evolving from interferon (IFN)-based therapy to direct-acting antiviral (DAA) agents, yet some safety concerns have arisen involving cardiac toxicity. In this study, we sought to better under

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238353d30252263d25f6c54929b5ed18
https://doi.org/10.1002/hep.27488

Durability of Response to Treatment among Antiretroviral‐Experienced Subjects: 48‐Week Results from AIDS Clinical Trials Group Protocol 359

Autor: Jon Cook, Charles B. Hicks, Bruce Coon, Richard Hutt, Margaret A. Fischl, David Pearson, Jan Clark, Candida T. Talabucon, Carol L. Brosgart, Joan Dragavon, Laura Ponticello, Janet Devine, Eugene Sun, Melissa Kerkau, Daniel C. Rodrigue, Donna Thee, Jeanne Berg, Mario Guerrero, Lyle Oshita, Jane L. Norris, Judy Aberg, Mark I. Becker, John Fuchs, Pablo Tebas, Guillermo J. Vázquez, Pamposh Kaul, Antoinette Kenton, Phyllis Barnett, Pascal J. de Caprariis, Michael Royal, Michelle Jack, Ann Walawander, Harold A. Kessler, Scott Souza, Sharon Shriver, Genice Hamilton, Susan E. Cohn, Hailong Cheng, John G. Gerber, Monica Millard, Sherree Wright, Linh Ngo, Gildon N. Beall, Debra Ogata-Arakaki, John Mc Neil, David M. Mushatt, Courtney V. Fletcher, Charles van der Horst, Karen Waterman, Ileana Lopez, David Katzenstein, Robert J. Fass, Joseph J. Eron, Edward P. Acosta, Stephen W. Lagakos, Hilda Mendoza, Jim Bruce, Michael F. Para, Sally Snyder, Mary Shoemaker, Mark A. Beilke, Tammy Powell, Margaret Nelson, Juan J.L. Lertora, Liliana Aguinada, Virginia Ramirez, M. Graham Ray, William W. Freimuth, Brenda Greenhill, Beverly Putnam, Aouie Carrera, Mary Albrecht, Michael F. Giordano, Stuart Carr, John M. Leedom, Charlotte Mills, Charles J. Gonzalez, Rebecca Becker, Richard Haubrich, Elizabeth Gimbel, D. Baker, Vivian Yuan, Andrea Weiss, Hongyu Jiang, Cheryl N. Karol, Kim Ingersol, Russell Strada, Paulette Mac Dougall, Carla Pettinelli, Glenna M. Auerback, Alice F. Mercado, Frances Canchola, Chris Helker, Susan A. Fiscus, X. Joan Hu, Janine R. Maenza, Henry S. Sacks, Robert Kalajian, Debbie Slamowitz, Robin Shepard, Margo Heath-Chiozzi, Michael J. Borucki, Ana Martinez, Olivia T. Ortiz, Suzanne Fiorillo, Jorge Santana, Michael S. Saag, Dena Duran, Steve Nowling, Jeff Taylor, Kristine Todd, Robert W. Coombs, Douglas D. Richman, Thomas C. Merigan, Robert Delapenha, Kenneth Wood, Harvey M. Friedman, Joseph Pulvirenti, Don Craven, Timothy W. Schacker, Ronald Swanstrom, Neel French, Judith Feinberg, Mark A. Jacobson, Judith Brown, Joseph Wheat, Ross G. Hewitt, James F. Rooney, Scott A. Smith, Bruce Peel, Doris Shank, Lisa Alexis, Roy M. Gulick, Andrea Christopher Belschner, Linda Meixner

Publikováno v: The Journal of Infectious Diseases. 186:626-633

The 24-week extension of AIDS Clinical Trials Group Protocol 359, a study of human immunodeficiency virus (HIV)‐infected, indinavir-experienced patients, was designed to study the durability of “salvage” treatment regimens. Patients received sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca3b1c2613fffeb024856928c7b68a2
https://doi.org/10.1086/342681

Immune Reconstitution in the First Year of Potent Antiretroviral Therapy and Its Relationship to Virologic Response

Autor: Brian L. Kotzin, Alan L. Landay, Michael M. Lederman, Elizabeth Connick, Marty St. Clair, Ana Martinez, Joana D'Arc Roe, Lawrence Fox, John Spritzler, Franck Rousseau, Harold A. Kessler, Anne Sevin, John M. Leonard, Daniel R. Kuritzkes, Margo Heath Chiozzi

Publikováno v: The Journal of Infectious Diseases. 181:358-363

The effects of 1 year of zidovudine, lamivudine, and ritonavir treatment on immune reconstitution were evaluated in 34 human immunodeficiency virus (HIV)-infected individuals. After 48 weeks of therapy, 20 (59%) subjects had

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8df27216b4c1189c6cb062ccbff327fd
https://doi.org/10.1086/315171